- Ipsen pursues acquisition of Memo Therapeutics for over €700M to add potrivutig, a monoclonal antibody for BK polyomavirus in kidney transplant patients, targeting 2029–2030 market entry.
- Ipsen (IPN) is in arbitration with Galderma over Relfydess. Ipsen is also developing botulinum program corabotase and exploring commercialization options for that asset.
TradingView
Key facts: Ipsen €700M+ Memo buy; Galderma arbitration; corabotase
Ipsen pursues acquisition of Memo Therapeutics for over €700M to add potrivutig, a monoclonal antibody for BK polyomavirus in kidney transplant patients, targeting 2029–2030 market